Jilin Jian Yisheng Pharmaceutical Co., Ltd. (002566.SZ)
CNY 6.89
(-0.14%)
CNY 6.89
(-0.14%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 595.6 Million CNY | -16.95% |
| 2022 | 717.17 Million CNY | 7.67% |
| 2021 | 666.08 Million CNY | 0.33% |
| 2020 | 663.86 Million CNY | 51.34% |
| 2019 | 438.66 Million CNY | -25.33% |
| 2018 | 587.49 Million CNY | -22.33% |
| 2017 | 756.4 Million CNY | -13.02% |
| 2016 | 869.67 Million CNY | -2.14% |
| 2015 | 888.64 Million CNY | 20.21% |
| 2014 | 739.23 Million CNY | 245.77% |
| 2013 | 213.79 Million CNY | 193.62% |
| 2012 | 72.81 Million CNY | 12.86% |
| 2011 | 64.51 Million CNY | -58.55% |
| 2010 | 155.66 Million CNY | 6.13% |
| 2009 | 146.67 Million CNY | 15.1% |
| 2008 | 127.43 Million CNY | -6.35% |
| 2007 | 136.08 Million CNY | 36.97% |
| 2006 | 99.35 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 571.33 Million CNY | -18.54% |
| 2024 Q3 | 688.68 Million CNY | 20.54% |
| 2024 Q1 | 701.32 Million CNY | 17.75% |
| 2023 Q3 | 739.93 Million CNY | 1.37% |
| 2023 Q1 | 732.06 Million CNY | 2.08% |
| 2023 FY | 595.6 Million CNY | -16.95% |
| 2023 Q4 | 595.6 Million CNY | -19.5% |
| 2023 Q2 | 729.96 Million CNY | -0.29% |
| 2022 Q3 | 665.38 Million CNY | -2.1% |
| 2022 Q1 | 650.35 Million CNY | -2.36% |
| 2022 Q4 | 717.17 Million CNY | 7.78% |
| 2022 FY | 717.17 Million CNY | 7.67% |
| 2022 Q2 | 679.67 Million CNY | 4.51% |
| 2021 Q1 | 632.11 Million CNY | -4.78% |
| 2021 Q2 | 547.59 Million CNY | -13.37% |
| 2021 Q3 | 614.47 Million CNY | 12.21% |
| 2021 FY | 666.08 Million CNY | 0.33% |
| 2021 Q4 | 666.08 Million CNY | 8.4% |
| 2020 Q1 | 419.97 Million CNY | -4.26% |
| 2020 Q2 | 409.75 Million CNY | -2.43% |
| 2020 Q3 | 551.13 Million CNY | 34.5% |
| 2020 Q4 | 663.86 Million CNY | 20.45% |
| 2020 FY | 663.86 Million CNY | 51.34% |
| 2019 Q2 | 510.71 Million CNY | -18.41% |
| 2019 Q1 | 625.94 Million CNY | 6.54% |
| 2019 FY | 438.66 Million CNY | -25.33% |
| 2019 Q3 | 506.24 Million CNY | -0.87% |
| 2019 Q4 | 438.66 Million CNY | -13.35% |
| 2018 Q1 | 732.27 Million CNY | -3.19% |
| 2018 FY | 587.49 Million CNY | -22.33% |
| 2018 Q4 | 587.49 Million CNY | -10.78% |
| 2018 Q3 | 658.46 Million CNY | 1.47% |
| 2018 Q2 | 648.9 Million CNY | -11.38% |
| 2017 Q2 | 809.38 Million CNY | -8.06% |
| 2017 Q3 | 819.48 Million CNY | 1.25% |
| 2017 Q4 | 756.4 Million CNY | -7.7% |
| 2017 FY | 756.4 Million CNY | -13.02% |
| 2017 Q1 | 880.33 Million CNY | 1.23% |
| 2016 Q4 | 869.67 Million CNY | -6.79% |
| 2016 Q3 | 933.04 Million CNY | -4.39% |
| 2016 Q2 | 975.86 Million CNY | 2.78% |
| 2016 FY | 869.67 Million CNY | -2.14% |
| 2016 Q1 | 949.45 Million CNY | 6.84% |
| 2015 FY | 888.64 Million CNY | 20.21% |
| 2015 Q2 | 971.83 Million CNY | 1.32% |
| 2015 Q1 | 959.16 Million CNY | 29.75% |
| 2015 Q4 | 888.64 Million CNY | -10.33% |
| 2015 Q3 | 991.05 Million CNY | 1.98% |
| 2014 Q3 | 397.66 Million CNY | -0.18% |
| 2014 Q1 | 320.61 Million CNY | 49.97% |
| 2014 FY | 739.23 Million CNY | 245.77% |
| 2014 Q4 | 739.23 Million CNY | 85.89% |
| 2014 Q2 | 398.4 Million CNY | 24.26% |
| 2013 Q3 | 96.43 Million CNY | 18.15% |
| 2013 Q2 | 81.61 Million CNY | 0.69% |
| 2013 Q1 | 81.05 Million CNY | 11.31% |
| 2013 FY | 213.79 Million CNY | 193.62% |
| 2013 Q4 | 213.79 Million CNY | 121.71% |
| 2012 Q4 | 72.81 Million CNY | -7.16% |
| 2012 Q3 | 78.42 Million CNY | 28.8% |
| 2012 Q2 | 60.89 Million CNY | -18.02% |
| 2012 Q1 | 74.27 Million CNY | 15.12% |
| 2012 FY | 72.81 Million CNY | 12.86% |
| 2011 Q3 | 98.62 Million CNY | -18.33% |
| 2011 FY | 64.51 Million CNY | -58.55% |
| 2011 Q2 | 120.75 Million CNY | -24.33% |
| 2011 Q1 | 159.57 Million CNY | 2.51% |
| 2011 Q4 | 64.51 Million CNY | -34.58% |
| 2010 Q4 | 155.66 Million CNY | 0.0% |
| 2010 FY | 155.66 Million CNY | 6.13% |
| 2009 FY | 146.67 Million CNY | 15.1% |
| 2009 Q2 | 122.75 Million CNY | 0.0% |
| 2009 Q4 | 146.67 Million CNY | 0.0% |
| 2008 FY | 127.43 Million CNY | -6.35% |
| 2007 FY | 136.08 Million CNY | 36.97% |
| 2006 FY | 99.35 Million CNY | 0.0% |